### Cerebral blood flow dependency on systemic arterial circulation in progressive multiple sclerosis

Dejan Jakimovski<sup>1</sup>, Niels Bergsland<sup>1,2</sup>, Michael G Dwyer<sup>1</sup>, Kunsang Choedun<sup>1</sup>, Karen Marr<sup>1</sup>, Bianca Weinstock-Guttman<sup>3</sup>, Robert Zivadinov<sup>1,4</sup>

<sup>1</sup>Department of Neurology, Buffalo Neuroimaging Analysis Center (BNAC), Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA; <sup>2</sup>IRCCS, Fondazione Don Carlo Gnocchi, Milan, Italy; <sup>3</sup>Department of Neurology, Jacobs Comprehensive MS Treatment and Research Center, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA; <sup>4</sup>Center for Biomedical Imaging at Clinical Translational Science Institute, University at Buffalo, State University of New York, Buffalo, NY, USA

Jacobs School of Medicine and Biomedical Sciences University at Buffalo

Medicine ciences



# 

## **Disclosures**:

University at Buffalo

• Kunsang Choedun, Karen Marr, and Niels Bergsland, have nothing to disclose.

Jacobs School of Medicine and Biomedical Sciences

- Dejan Jakimovski serves as Associate Editor of Clinical Neurology and Neurosurgery and is reimbursed by Elsevier B.V.
- Michael G. Dwyer has received personal compensation from Keystone Heart for consultant fees. He received financial support for research activities from Bristol Myers Squibb, Mapi Pharma, Keystone Heart, Protembis and V-WAVE Medical.
- Bianca Weinstock-Guttman received honoraria as a speaker and/or as a consultant for Biogen Idec, Teva Pharmaceuticals, EMD Serono, Genzyme, Sanofi, Genentech, Novartis, Mallinckrodt, Celgene, Abbvie and Acorda. Dr Weinstock-Guttman received research funds from Biogen Idec, Teva Pharmaceuticals, EMD Serono, GenzymeGenentech, Sanofi, Novartis, and Acorda.
- Robert Zivadinov has received personal compensation from Bristol Myers Squibb, EMD Serono, Sanofi, Keystone Heart, Protembis
  and Novartis for speaking and consultant fees. He received financial support for research activities from Sanofi, Novartis, Bristol
  Myers Squibb, Octave, Mapi Pharma, Keystone Heart, Protembis and V-WAVE Medical.

1

2





## Jacobs School of Medicine and Biomedical Sciences

### Methods – continued:

#### MRI acquisition and analysis:

- Patients underwent an MRI examination on a 3.0T GE Signa Excite scanner (Milwaukee, WI, USA) with eight-channel head and neck coil.
- The MRI protocol included an axial 3D spoiled gradient recalled (SPGR) T1-weighted image (WI), an axial 2D T2-WI Fluid Attenuated Inversion Recovery (FLAIR) and dynamic susceptibility contrast perfusionweighted imaging (DSC-PWI) sequence.
- T2 and T1-LV were derived using semi-automated, threshold and contour segmentation, while WBV was obtained with the cross-sectional package from Structural Image Evaluation, using Normalisation, of Atrophy (SIENAX; version 2.6, Oxford Centre for Functional Magnetic Resonance Imaging of the Brain, Oxford, UK).<sup>1</sup>
- JIM Perfusion Toolkit was used to produce the PWI-derived measures of mean transit time (MTT) and time-to-peak (TTP) time. The structural and perfusion segmentations were co-registered and aligned in the same MRI space. Mean values for NAWB and GM MTT and TTP were calculated.

#### Statistical analyses:

- All statistical analyses were performed on SPSS version 26.0 (IBM, Armonk, NY, USA). Data distributions were evaluated using the Kolmogorov-Smirnov test and visual inspection of the Q-Q plots.
- The comparison of demographic and clinical characteristics parametric and non-parametric tests as appropriate.
- Moreover, age, sex, BMI and WBV-adjusted linear regression models determined whether SABF explains additional variance of the perfusion-based measures.
- Patients were further divided into SABF quartiles and the DSC-MRI measures were compared with age, sex, BMI and WBVadjusted analysis of covariance (ANCOVA). The pair-wise comparisons from the ANCOVA analysis were Bonferroni adjusted.

SABF – systemic arterial blood flow, BMI – body mass index, WBV – whole brain volume, NAWB – normal-appearing whole brain, GM – gray matter, MTT – mean transit time, TTP – time-to-peak.

5

•	Jacobs School of Medicine and Biomedical Sciences
---	---

## **Results:**

1. Smith SM et al. Neuroimage 2002;17:479-489.

	MS (n=118)	CIS/RRMS (n=75)	PMS (n=43)	CIS/RRMS vs. PMS p-value
Female, n (%)	89 (75.4)	55 (73.3)	34 (79.1)	0.715
Age, mean (SD)	53.52 (11.6)	49.25 (11.3)	60.97 (7.8)	< 0.001
BMI, mean (SD)	27.6 (5.9)	27.6 (6.1)	27.6 (5.8)	0.945
Disease duration, mean (SD)	20.1 (10.3)	16.5 (9.1)	26.2 (9.5)	< 0.001
EDSS, median (IQR)	3.0 (1.5-6.0)	2.0 (1.5-3.0)	6.0 (3.75-6.5)	< 0.001
MSSS, median (IQR)	2.3 (1.1-5.0)	1.5 (09-3.1)	5.6 (2.7-6.3)	< 0.001
T25FWT, median (IQR)	5.26 (4.5-7.3)	4.8 (4.4-5.7)	7.4 (6.1-11.8)	< 0.001
9HPT, median (IQR)	23.1 (19.7-28.3)	21.1 (18.8-23.8)	26.2 (24.3-34.5)	< 0.001
Hypertension diagnosis, n (%)	21 (17.8)	8 (10.7)	13 (30.2)	0.012
SBP, mean (SD)	124.7 (13.7)	125.1 (12.7)	123.9 (15.4)	0.68
SABF, mean (SD)	947.7 (262.2)	954.4 (260.3)	928.2 (279.0)	0.610
WBV, mean (SD)	1451.2 (94.4)	1485.4 (81.1)	1393.5 (87.5)	0.006*
NAWB MTT	3.29 (0.7)	3.22 (0.7)	3.44 (0.8)	0.139
GM MTT	3.26 (0.8)	3.17 (0.7)	3.42 (0.9)	0.106
NAWB TTP	7.08 (1.3)	7.01 (1.3)	7.19 (1.1)	0.469
GM TTP	7.08 (1.3)	6.99 (1.4)	7.22 (1.2)	0.357
DMT, n (%)				
Interferon-β	40 (33.9)	28 (37.3)	12 (27.9)	
Glatiramer acetate	30 (25.4)	18 (24.0)	12 (27.9)	
Natalizumab	4 (3.4)	3 (4.0)	1 (2.3)	0.655
Oral medications	12 (11.9)	8 (13.3)	4 (9.4)	0.035
Off-label medications	4 (3.4)	2 (2.7)	2 (4.7)	
No DMT use	26 (22.0)	14 (18.7)	12 (27.9)	



5

**BNAC** 

 Higher systolic blood pressure was significantly associated with lower SABF (r==0.265, age and BMIadjusted p=0.006). These findings were driven only by the PMS subgroup.

Legend: MS – multiple sclerosis, CIS – clinically isolated syndrome, RRMS – relapsing-remitting multiple sclerosis, PMS – progressive multiple sclerosis, BMI – body mass index, EDSS – Expanded Disability Status Scale, SBP – systolic blood pressure, SABF – systemic attrictal blood flow, WBV – whole brain volume, DMT – disease modifying therapy, SD – standard deviation, IQR – interquartile range, NAWB – normal-appearing whole brain, GM – gray matter, MTT – mean transit time, TTP – time-to-peak. Data regarding DMT status was missing for 2 CIS/RRMS patients.

The groups were compared with  $\chi^2$  and Student's t-test as a ppropriate, P-value lower than 0.05 was considered statistically significant and shown in bold. \* - age-adjusted analysis of covariance (ANCOVA)

Age and disease duration are shown in years, SABF is shown as milliliters per minute (mL/min) and WBV is shown as mL. Both MTT and TTP measures are absolute data in seconds and shorter MTT and TTP times represent greater blood flow at the capillary level. 6

### Jacobs School of Medicine and Biomedical Sciences

## Results - continued:

Table. Adjusted relationship between cerebral and systemic blood flow in PMS patients.

NAWB TTP	R <sup>2</sup>	SE of estimate	t-statistics	standardized β	p-value
Block 1	0.137	1.096			
Age			1.678	0.26	0.103
Sex			0.374	0.057	0.711
BMI			-0.84	-0.141	0.407
WBV			0.87	0.149	0.391
Block 2	0.269	1.024			
SABF			-2.405	-0.384	0.022
GM TTP	R <sup>2</sup>	SE of estimate	t-statistics	standardized β	p-value
Block 1	0.144	1.133			
Age			1.648	0.257	0.109
Sex			0.397	0.061	0.694
BMI			-1.021	-0.173	0.315
WBV	Ļ		0.86	0.149	0.396
Block 2	0.254	1.074			
SABF			-2.174	-0.351	0.037

The linear regression models are built with first block which force-enters and corrects for the effect of age, sex, BMI and WBV. The second step-wise block is built only if SABF provides additional and significant explanatory power.

• After correction for demographic covariates and WBV, the SABF in PMS patients remained significantly associated with the TTP of NAWB and GM.

**BNAC** 

7

• Addition of SABF resulted with significant R<sup>2</sup> increase from 0.137 to 0.269, additionally explaining 13.2% of the remaining NAWB TTP variance.

• After adjusting for age, sex, BMI and WBV effects, higher SABF remained significantly associated with shorter GM TTP as well.

PMS – progressive multiple selerosis, SABF – systemic arterial blood flow, BMI – body mass index, WBV – whole brain volume, NAWB – normal-appearing whole brain, GM – gray matter, TTP – time-to-peak.





• Hypertension-induced decreases in SABF would particularly affect MS patients with CVR impairment and potentially worsen the disability progression.

PMS – progressive multiple sclerosis, SABF – systemic arterial blood flow, CIS – clinically isolated syndrome, RRMS – relapsing remitting multiple sclerosis, BMI – body mass index, WBV – whole brain volume, CVR – cerebrovascular reactivity,

### Summary:

• Cerebral perfusion in PMS patients is directly associated and potentially dependent on the SABF, but not in the CIS/RRMS patients.

BNAC

- These associations remained significant after correcting for effects of aging and BMI as well as total WBV.
- The discrepancies between the MS subtypes may be attributed to failure in the CVR, where PMS patients would not be able to appropriately redistribute the insufficient inflowing arterial blood flow.

### **Conclusions:**

 The direct relationship between systemic and cerebral blood flow seen in PMS patients may suggest failure in cerebrovascular reactivity mechanisms and insufficient perfusion control.